RecruitingNCT07271069
Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
Real-world Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis: A Chart Review Study
Sponsor
Bristol-Myers Squibb
Enrollment
150 participants
Start Date
Jan 29, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to evaluate the effectiveness and safety of ozanimod vs azathioprine for the treatment of ulcerative colitis (UC) in real-world clinical practice in Japan
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Participants with Ulcerative Colitis (UC) provided written consent to participate in the study
- Participants who are aged ≥ 18 years at the earlier date of either initiation of treatment with ozanimod or azathioprine or obtaining consent
- Starting dose of oral steroid ≥ 30 mg/day (prednisolone equivalent)
- Administration of ozanimod or azathioprine started after oral steroid administration, and ozanimod or azathioprine administered concomitantly with steroids (excluding patients who started oral steroids and ozanimod or azathioprine on the same day)
- In the ozanimod group, patients with notable clinical symptoms due to the primary disease (rectal bleeding subscore ≥ 1 point or total PRO2 score ≥ 2 points) remained at the start of ozanimod administration
- In the azathioprine group, patients who started azathioprine treatment after February 2019
Exclusion Criteria4
- Participants with symptoms of UC with no change or increase in Patient-Reported Outcome 2 (PRO2) from the time of initiating oral steroid administration after 2 weeks of administration of ≥ 30 mg/day (prednisolone equivalent) of oral steroids
- Participants with complications requiring continued steroid use (excluding topically acting steroids for inhalation or topical application)
- Participants who participated in other clinical studies involving interventions during the observation period
- Participants judged to be inappropriate for enrollment in this study by the investigator at each participating study site
Interventions
DRUGOzanimod
According to the product label
DRUGAzathioprine
According to the product label
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07271069
Related Trials
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
NCT072375165 locations
Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD
NCT074319832 locations
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease
NCT073005531 location
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT0711352266 locations
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT0661999040 locations